skip to main content

Lowenstein Sandler LLP | The contents of this website contain attorney advertising. | Results may vary depending on your particular facts and legal circumstances.

Search
Smart Search Icon
Header Search
view all search results
Search Close
Hamburger
profile Icon for Mobile

Nicholas G. Mehler

Partner

New York / New Jersey
T: +1 973.597.2364 F: +1 973.597.2365 nmehler@lowenstein.com
  • BIO
  • EXPERIENCE
  • HONORS & AWARDS
  • NEWS & INSIGHTS

See more section

Nicholas Mehler has over 25 years of experience advising life sciences, software and other technology-focused businesses on a wide range of licensing and commercial transactions. Clients ranging from startup ventures to Fortune 500 companies value his expertise with development and licensing deals, pharmaceutical product acquisitions and divestitures, strategic alliances, manufacturing agreements, sponsored research agreements, CRO agreements and distribution agreements.

Nick prides himself in taking a practical approach to negotiations and keeping the focus on his client’s business goals. 

  • Represented Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) in its exclusive license agreement with CSPC Pharmaceutical Group Limited to in-license rights to a novel, clinical-stage antibody drug conjugate targeting Nectin-4.
  • Represented Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) in its asset purchase agreement with Upsher-Smith Laboratories, LLC to acquire rights to two FDA-approved migrane therapies Zembrace® SymTouch® (sumatriptan injection) and Tosymra® (sumatriptan nasal spray).
  • Represented Cingulate Inc. (NASDAQ: CING) in its joint commercialization agreement with Indegene, Inc. to provide commercialization services for Cingulate’s lead candidate CTx-1301, a novel ADHD therapy.
  • Represented PAI Holdings, LLC d/b/a PAI Pharma in acquisition of ANDA assets from the chapter 7 bankruptcy estate of Akorn Operating Company LLC.
  • Represented Catalent, Inc. (NYSE: CTLT) and its Redwood Bioscience subsidiary in its exclusive license agreement with Exelixis, Inc. to out-license three antibody-drug conjugate target programs to Exelixis, and in its separate collaboration, license and exclusive option agreement for the development of multiple antibody-drug conjugates using Catalent’s proprietary conjugation technology.
  • Represented Catalent, Inc. (NYSE: CTLT) in its license agreement with Bhami Research Laboratory to in-license formulation technology for the subcutaneous delivery of high-concentration biologic therapies.
  • Represented PAI Holdings, LLC d/b/a PAI Pharma as stalking horse bidder and successful bidder at auction to acquire portfolio of over 70 ANDAs and NDAs from the chapter 11 bankruptcy estate of Teligent, Inc.
  • Represented Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) in its asset purchase agreement with Dr. Reddy's Laboratories S.A. for acquisition of rights to E7777 (denileukin diftitox), a late-stage oncology immunotherapy.
SEE MORE

CLICK HERE FOR AWARD INFORMATION & METHODOLOGY

No aspect of these advertisements has been approved by the highest court of any state.

Education

  • New York University School of Law (J.D. 1998), cum laude

    Yale University (B.A. 1994), magna cum laude

Admissions

  • New York
  • New Jersey

Related Areas

Additional Resources